CNS Pharmaceuticals, Inc.

Overview

Compare with another stock.

• TickerCNSP on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersHouston, United States²
• Incorporated inNV³
• Business address2100 West Loop South, Suite 900, Houston, Tx 77027³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI529900FDJ7WGF2Q7UN44²
• StatusActive²
• LEI statusIssued and current²
• Registered addressc/o Corporation Service Company, 112 North Curry Street, 89703 Carson City, United States²
• Registered withBusiness Center (Secretary of State), E0354342017-0²

See how the biggest companies compare on our leaderboards

Chimeric antigen receptor T-cell (“CAR-T”) therapy has achieved durable remissions in subsets of hematologic malignancies.⁴ From its latest annual report

Corporate structure

CNS Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CNS Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our corporate and executive offices are located in a leased facility in Houston, Texas. We believe our facilities are sufficient to meet our current needs and that suitable space will be available as and when needed. We do not own any real property.

Item 2 of the 10-K filed Mar 31, 2026.⁴

Leadership

Who has led CNS Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRami Levin Jan 2, 2026 to now¹³
• Chief executive officerJohn M. Climaco Nov 8, 2019 to Jan 2, 2026¹⁴
• PresidentRami Levin Jan 2, 2026 to now¹³
• Chief financial officerSteve O'Loughlin Mar 4, 2026 to now¹⁵

Timeline

1. Oct 2, 20268-K Executive or director change; Shareholder vote²⁵
2. Jul 2, 20268-K Regulation FD disclosure²⁶
3. May 4, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change²⁷
4. Mar 11, 20268-K Regulation FD disclosure²⁸
5. Mar 2, 20268-K Executive or director change²⁹
6. Feb 17, 20268-K Executive or director change³⁰
7. Jan 2, 2026New chief executive Rami Levin becomes CEO¹³
8. Dec 17, 20258-K Executive or director change³¹
9. Nov 21, 20258-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote³²
10. Jul 22, 20258-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events³³
11. Jul 15, 20258-K Regulation FD disclosure³⁴
12. May 15, 20258-K Entered a material agreement³⁵
13. Apr 9, 20258-K Regulation FD disclosure³⁶
14. Nov 8, 2019New chief executive John M. Climaco becomes CEO¹⁴
15. Jul 27, 2017Founded CNS Pharmaceuticals, Inc. is founded²

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026³⁷

When it reported results

1. May 16, 2024Reported quarterly or annual results³⁸
2. Apr 1, 2024Reported quarterly or annual results³⁹
3. Nov 15, 2023Reported quarterly or annual results⁴⁰
4. Aug 14, 2023Reported quarterly or annual results⁴¹
5. May 15, 2023Reported quarterly or annual results⁴²
6. Aug 15, 2022Reported quarterly or annual results⁴³
7. May 16, 2022Reported quarterly or annual results⁴⁴
8. Mar 3, 2022Reported quarterly or annual results⁴⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

280 filings to the SEC since October 2021: 9 annual reports, 15 quarterly reports, 72 major events, 71 insider forms, 14 large holders, 1 private raises, 98 other. The latest 20:

1. Oct 2, 20268-K EDGAR
2. Aug 25, 2026DEFA14A EDGAR
3. Aug 21, 2026DEF 14A DEFINITIVE NOTICE AND PROXY STATEMENT EDGAR
4. Aug 18, 20264 EDGAR
5. Aug 18, 20264 EDGAR
6. Aug 18, 20263 EDGAR
7. Aug 14, 2026SCHEDULE 13G/A EDGAR
8. Aug 12, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
9. Jul 2, 20268-K EDGAR
10. May 26, 2026EFFECT EDGAR
11. May 26, 2026424B3 424B3 PROSPECTUS EDGAR
12. May 22, 2026CORRESP EDGAR
13. May 22, 2026UPLOAD EDGAR
14. May 20, 20264 EDGAR
15. May 19, 2026D EDGAR
16. May 19, 2026S-3 FORM S-3 REGISTRATION STATEMENT EDGAR
17. May 15, 2026SCHEDULE 13G/A EDGAR
18. May 14, 202610-Q FORM 10-Q FOR MAR 2026 EDGAR
19. May 4, 20268-K EDGAR
20. Apr 30, 202610-K/A AMENDMENT #1 TO FORM 10-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

31 open-market trades by officers, directors and large owners since October 2021: 14 buys and 17 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Ikarian Capital, LLCSCHEDULE 13G/A, 2 filings Apr 17, 2026 to Aug 14, 2026⁴⁶
• Stonepine Capital Management, LLCSCHEDULE 13G/A, 3 filings Nov 4, 2025 to May 15, 2026⁴⁷
• ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 5 filings Feb 14, 2023 to Nov 14, 2025⁴⁸
• Cortice Biosciences, Inc.SC 13D, 1 filing Aug 2, 2024⁴⁹
• Robert ForsterSC 13G, 2 filings Jun 25, 2024 to Jul 2, 2024⁵⁰
• Waldemar PriebeSC 13G, 1 filing Aug 1, 2023⁵¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. May 4, 2026Raised $22.5 million in a private offering of equity⁵³ Form D: 13 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How CNS Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCNS Pharmaceuticals, Inc.¹
• CIK0001729427
• Employer ID (EIN)82-2318545⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁴
• Incorporated inNevada⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address2100 West Loop South, Suite 900, Houston, TX 77027¹
• Phone1-800-946-9185¹
• Shares outstanding1,461,449 as of Aug 11, 2026¹²
• Public float$5.0M as of Jun 30, 2025⁴
• AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceMar 13, 2018¹
• Filings390 in all: 8-K (100), 4 (68), CORRESP (43), 10-Q (21), 3 (15), EFFECT (12), UPLOAD (12), S-1/A (10)¹
  All 43 form types

  424B5 (8), DEF 14A (8), S-1 (8), 10-K (7), 4/A (7), 10-K/A (6), 424B3 (5), 424B4 (5), PRE 14A (5), S-3 (5), SC 13G (4), SCHEDULE 13G/A (4), 1-A/A (3), 8-K/A (3), DRS (3), FWP (3), S-8 (3), SCHEDULE 13G (3), DEFA14A (2), SC 13G/A (2), 1-A (1), 1-A-W (1), 8-A12B (1), ARS (1), C (1), C-AR (1), C-TR (1), C-U (1), CERT (1), D (1), DEFR14A (1), DOS (1), DRSLTR (1), RW (1), SC 13D (1)

• Latest filingsAnnual report (10-K) Mar 31, 2026
  Quarterly report (10-Q) Aug 12, 2026
  Proxy statement (DEF 14A) Aug 21, 2026
  Latest 8-K (8-K) Oct 2, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks CNS Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 36 risks under these headings, as written.⁴

• Risks Related to the Company’s Business and Industry
• Our future success depends on our ability to identify, acquire or license new drug candidates, and we may not be successful in doing so.
• Any drug candidates we acquire or license may require significant additional development, and there can be no assurance that such candidates will prove to be safe, effective or commercially viable.
• We may not have access to sufficient capital to pursue acquisition or licensing opportunities, which could limit our ability to expand our pipeline.
• We will require substantial funding to execute our new corporate strategy, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.
• The report of our independent registered public accounting firm expresses substantial doubt about our ability to continue as a going concern. Such “going concern” opinion could impair our ability to obtain financing.
• We have never been profitable, we have no products approved for commercial sale, and we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability is unproven, and we may never achieve or sustain profitability. Therefore, we may not be able to continue as a going concern.
• We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance.
• We cannot be certain that any of our future product candidates will receive regulatory approval, and without regulatory approval we will not be able to market or commercialize them.
• Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for our product candidates.
• We have never completed a clinical trial or submitted an NDA before, and any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.
• If a future product candidate is found to be unsafe or ineffective, we will not be able to obtain regulatory approval for it and our business would be materially and possibly irreparably harmed.

Legal proceedings

From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. However, we are currently not a party to any pending legal actions. We have insurance policies covering any potential losses where such coverage is cost effective.

We are not at this time involved in any additional legal proceedings that we believe could have a material effect on our business, financial condition, results of operations or cash flows.

The opening of Item 3, Legal Proceedings.⁴